Cell surface receptor-targeted therapy of acute myeloid leukemia: A review

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 5, 2000, Pages 459-476

  Frankel, A E ^a   Sievers, E L ^b   Scheinberg, D A ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BUSULFAN; CELL SURFACE PROTEIN; CELL SURFACE RECEPTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; CYTOTOXIC AGENT; FC RECEPTOR; GEMTUZUMAB OZOGAMICIN; IODINE 131; LIGAND; METHOTREXATE; MONOCLONAL ANTIBODY CD33; MONOCLONAL ANTIBODY CD45; MONOCLONAL ANTIBODY M 195; MURINE MONOCLONAL ANTIBODY; TOXIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CELL ADHESION; CELL KILLING; CLINICAL TRIAL; HUMAN; LUNG TOXICITY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; REMISSION; REVIEW;

EID: 0033679426     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2000.15.459     Document Type: Review

References (84)

1. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia
2. Cellular biology of acute myelogenous leukemia
3. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
4. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo
5. Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells
6. Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood
7. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia
8. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-MO)
9. Clonal selection of CD56+t(8;21) AML blasts: Further suggestion of the adverse clinical significance of this biological marker?
10. Prognistic value of internal tandem duplication of the FLT3 gene in childhood acute myelgenous leukemia
11. C-kit mutations in core binding factor leukemias
12. Comparison of the efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients <60 and >60 years of age with AML in first relapse
13. Phase I trial of fusion toxin DTGM containing human GM-CSF fused to truncated diphtheria toxin in adults with relapsed or refractory acute myelgenous leukemia (AML)
14. Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed
15. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM 195 in acute promyelocytic leukemia (APL)
16. Myeloid associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies
17. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
18. Monoclonal antibody M 195: A diagnostic marker for acute myelogenous leukemia
19. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors
20. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft
21. Human homologue of murine T200 glycoprotein
22. Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
23. Human GMCSF molecular cloning of the complementary DNA and purification of the natural and recombinant proteins
24. Molecular physiology of granulocytemacrophage colony-stimulating factor
25. Interleukin-3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: Receptor heterogeneity and relationship to growth factor responsiveness
26. Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor in normal human myeloid cells
27. Distribution of receptors for granulocyte macrophage colony stimulating factor receptors on immature CD34+ bone marrow cells, differentiating monomyeloid progenitors, and mature blood cell subsets
28. Variable cytotoxicity of diphtheria toxin 388-granulocyte macrophage colony stimulating factor (DT388-GMCSF) fusion protein for acute myelogenous leukemia (AML) stem cells
29. Preparation of genetically engineered monoclonal antibodies for human immunotherapy
30. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
31. Chimeric and humanized antibodies with specificity for the CD33 antigen
32. Refined crystal structure of human granulocyte-macrophage colony-stimulating factor
33. Molecular modeling of the GM-CSF and IL-3 receptor complexes
34. Biological and immunological features of humanized M 195 (anti-CD33) monoclonal antibodies
35. Regulation of the complement membrane attack pathway
36. Signal transduction by immunoglobulin Fc receptors
37. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
38. 1
39. Characterization of the in vitro cyclization chemistry of calicheamicin and its relation to DNA cleavage
40. 1 and DNA: Molecular recognition process responsible for site-specificity
41. 1: An antitumor antibiotic that cleaves doublestranded DNA site specifically
42. 90Y
43. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for Yttrium labeling of monoclonal antibodies
44. Improved in vivo stability and tumor targeting of bismuth-labeled antibody
45. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell
46. The crystal structure of diphtheria toxin
47. ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products
48. DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis
49. Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells
50. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics
51. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque
52. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia
53. A phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity
54. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias
55. Synthesis of C-functionalized trans-cyclohexyldiethlene-triaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter
56. 213Bi-labeled antibody constructs for clinical use
57. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry
58. Diphtheria toxin fusion proteins
59. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells
60. High level synthesis and maximal purification of the recombinant diphtheria fusion toxin DTGM for phase I clinical trials
61. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia
62. A phase I trial of monoclonal antibody M 195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide
63. Molecular remission induction without relapse after anti-CD33 monoclonal antibody HuM 195 in acute promyelocytic leukemia (APL)
64. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM 195 in myelogenous leukemia
65. A phase I trial of humanized monoclonal antibody HuM 195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia
66. Humanized monoclonal anti-CD33 antibody HuM 195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML): Preliminary report of a phase II study
67. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias
68. Sequential targeted therapy for relapsed acute promyelocytic leukemic with all-trans retinoic acid and anti-CD33 monoclonal antibody M 195
69. [131I]-Anti-CD45 antibody plus busulfan/cyclophosphamide in match-related transplants for AML in first remission
70. Phase I trial of targeted alphaparticle therapy for myeloid leukemias with Bismuth-213-HuM 195 (anti-CD33)
71. Potential for myeloablation with Yttrium-90-HuM 195 (anti-CD33) in myeloid leukemia
72. The multidrug resistance phenotype confers immunological resistance
73. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (CMA-676) shows non-apoptotic cytocidal effect on CD33positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines
74. Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy
75. Overall survival (OS) advantage to simultaneous chemotherapy (Crx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
76. Treatment of patients with lowgrade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
77. Receptor-mediated uptake of an extracellular Bcl-x(L) fusion protein inhibits apoptosis
78. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: Possible sites for intervention with anti-neoplastic drugs
79. Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targeting the common cytokine binding site of their receptors
80. Humanized M 195 monoclonal antibody conjugated to recombinant gelonin: An anti-CD33 immunotoxin with antileukemic activity
81. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias
82. Radiotoxicity of systemically administered 211 At-labeled human/mouse chimeric monoclonal antibody: A long-term survival study with histologic analysis
83. Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells
84. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein